The worldwide burden of Plasmodium vivax malaria has more than halved from an estimated 17.3 to 6.5 million cases between 2010 and 2019. This resulted from increased deployment of conventional malaria control measures (rapid diagnostic tests, effective antimalarial treatment, vector control) and significant global investment in malaria elimination. There is no generally available P. vivax vaccine, nor is there likely to be one in the near future.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: